SLGL
Sol-Gel Technologies Ltd.
NASDAQ · ILHealthcareBiotechnology
$80.10-3.73%
Price as of Jul 20, 2026
SLGL financials
Sol-Gel Technologies Ltd. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $19.4M | $11.5M | $1.6M | $3.9M |
| Cost of revenue | $0.00 | $233.0K | $342.0K | $12.7M |
| Gross profit | $19.4M | $11.3M | -$22.0M | -$8.8M |
| Operating expenses | $26.9M | $23.3M | $7.3M | $7.4M |
| Operating income | -$7.5M | -$12.0M | -$29.3M | -$16.2M |
| Net income | -$6.1M | -$10.6M | -$27.2M | -$14.9M |
| EBITDA | -$7.4M | -$10.3M | -$29.0M | -$15.7M |
| Basic EPS | $-2.20 | $-0.38 | $-1.01 | $-0.65 |
| Diluted EPS | $-2.20 | $-0.38 | $-1.01 | $-0.65 |
| Balance sheet | ||||
| Cash & equivalents | $11.0M | $19.5M | $7.5M | $12.4M |
| Total assets | $29.9M | $35.8M | $45.3M | $46.6M |
| Total liabilities | $7.1M | $7.0M | $6.6M | $4.4M |
| Stockholders’ equity | $22.8M | $28.9M | $38.6M | $42.2M |
| Total debt | $991.0K | $1.3M | $1.7M | $772.0K |
| Net debt | -$10.0M | -$18.2M | -$5.9M | -$11.7M |
| Cash flow | ||||
| Operating cash flow | $322.0K | -$13.9M | -$17.7M | -$9.5M |
| Capital expenditure | -$47.0K | -$2.0K | -$134.0K | -$171.0K |
| Free cash flow | $275.0K | -$13.9M | -$17.9M | -$9.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |